Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 6.39% is 17% above its 5-year average of 5.44%, around the middle of its 5-year range (1.81%–8.76%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.62% above its 12-month average of 6.17%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 6.39%.
RETURN ON EQUITY (ROE)
6.39%
RETURN ON EQUITY (ROE) AVG TTM
6.17%
RETURN ON EQUITY (ROE) AVG 3Y
6.60%
RETURN ON EQUITY (ROE) AVG 5Y
5.44%
RETURN ON EQUITY (ROE) AVG 10Y
4.73%
RETURN ON EQUITY (ROE) AVG 15Y
6.68%
RETURN ON EQUITY (ROE) AVG 20Y
8.50%
CURRENT VS TTM AVG
+3.62%
CURRENT VS 3Y AVG
-3.13%
CURRENT VS 5Y AVG
+17.45%
CURRENT VS 10Y AVG
+35.21%
CURRENT VS 15Y AVG
-4.28%
CURRENT VS 20Y AVG
-24.85%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
-50.88%
vs the sector median at left
Zimmer Biomet Holdings, Inc.
Market Cap
$18.45B
Return on Equity (ROE)
6.39%
TTM Avg
6.17%
3Y Avg
6.60%
5Y Avg
5.44%
Market Cap
$19.74B
Return on Equity (ROE)
-2.88%
TTM Avg
-13.64%
3Y Avg
-4.29%
5Y Avg
-4.38%
Market Cap
$17.09B
Return on Equity (ROE)
113.29%
TTM Avg
73.63%
3Y Avg
65.34%
5Y Avg
49.74%
Market Cap
$16.00B
Return on Equity (ROE)
3.29%
TTM Avg
3.59%
3Y Avg
3.35%
5Y Avg
7.68%
Market Cap
$21.00B
Return on Equity (ROE)
20.48%
TTM Avg
18.68%
3Y Avg
17.25%
5Y Avg
16.03%
Market Cap
$15.38B
Return on Equity (ROE)
29.88%
TTM Avg
23.51%
3Y Avg
17.50%
5Y Avg
13.68%
Market Cap
$14.67B
Return on Equity (ROE)
46.68%
TTM Avg
29.72%
3Y Avg
22.87%
5Y Avg
17.28%
Market Cap
$13.64B
Return on Equity (ROE)
-57.18%
TTM Avg
-651.33%
3Y Avg
-315.37%
5Y Avg
-198.08%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. (ZBH) | $18.45B | 6.39% | 6.17% | 6.60% | 5.44% |
| Viatris Inc. (VTRS)vs › | $19.74B | -2.88% | -13.64% | -4.29% | -4.38% |
| Medpace Holdings, Inc. (MEDP)vs › | $17.09B | 113.29% | 73.63% | 65.34% | 49.74% |
| STERIS plc (STE)vs › | $19.98B | 11.17% | 10.12% | 7.00% | 7.00% |
| Revvity, Inc. (RVTY)vs › | $16.00B | 3.29% | 3.59% | 3.35% | 7.68% |
| United Therapeutics Corporation (UTHR)vs › | $21.00B | 20.48% | 18.68% | 17.25% | 16.03% |
| Solventum Corporation (SOLV)vs › | $15.38B | 29.88% | 23.51% | 17.50% | 13.68% |
| Exelixis, Inc. (EXEL)vs › | $14.67B | 46.68% | 29.72% | 22.87% | 17.28% |
| Tempus AI, Inc. (TEM)vs › | $13.64B | -57.18% | -651.33% | -315.37% | -198.08% |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.39B | -8.40% | -2.13% | 6.32% | 9.65% |
ROE
6.4%
ROA
3.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 6.39% |
| 2026-03-31 | 6.01% |
| 2025-12-31 | 5.55% |
| 2025-09-30 | 6.31% |
| 2025-06-30 | 6.57% |
| 2025-03-31 | 7.37% |
| 2024-12-31 | 7.25% |
| 2024-09-30 | 8.76% |
| 2024-06-30 | 7.83% |
| 2024-03-31 | 7.65% |
| 2023-12-31 | 8.20% |
| 2023-09-30 | 3.79% |
| 2023-06-30 | 4.09% |
| 2023-03-31 | 3.70% |
| 2022-12-31 | 1.93% |
| 2022-09-30 | 2.27% |
| 2022-06-30 | 1.89% |
| 2022-03-31 | 1.81% |
| 2021-12-31 | 3.17% |
| 2021-09-30 | 6.45% |
| 2021-06-30 | 7.28% |
| 2021-03-31 | 4.56% |
| 2020-12-31 | -1.14% |
| 2020-09-30 | -1.28% |
| 2020-06-30 | 0.32% |
| 2020-03-31 | 3.17% |
| 2019-12-31 | 9.13% |
| 2019-09-30 | -0.75% |
| 2019-06-30 | -3.08% |
| 2019-03-31 | -2.67% |
| 2018-12-31 | -3.36% |
| 2018-09-30 | 14.35% |
| 2018-06-30 | 14.03% |
| 2018-03-31 | 14.08% |
| 2017-12-31 | 15.46% |
| 2017-09-30 | 6.24% |
| 2017-06-30 | 6.93% |
| 2017-03-31 | 5.00% |
| 2016-12-31 | 3.16% |
| 2016-09-30 | 3.73% |
| 2016-06-30 | 2.37% |
| 2016-03-31 | 0.87% |
| 2015-12-31 | 1.49% |
| 2015-09-30 | 1.77% |
| 2015-06-30 | 3.23% |
| 2015-03-31 | 10.30% |
| 2014-12-31 | 11.11% |
| 2014-09-30 | 12.34% |
| 2014-06-30 | 12.22% |
| 2014-03-31 | 12.25% |
| 2013-12-31 | 12.08% |
| 2013-09-30 | 11.05% |
| 2013-06-30 | 11.92% |
| 2013-03-31 | 13.39% |
| 2012-12-31 | 12.88% |
| 2012-09-30 | 13.03% |
| 2012-06-30 | 13.53% |
| 2012-03-31 | 13.47% |
| 2011-12-31 | 13.81% |
| 2011-09-30 | 11.41% |
| 2011-06-30 | 10.62% |
| 2011-03-31 | 10.24% |
| 2010-12-31 | 10.34% |
| 2010-09-30 | 12.32% |
| 2010-06-30 | 11.79% |
| 2010-03-31 | 12.61% |
| 2009-12-31 | 12.72% |
| 2009-09-30 | 12.20% |
| 2009-06-30 | 13.69% |
| 2009-03-31 | 14.61% |
| 2008-12-31 | 15.02% |
| 2008-09-30 | 16.81% |
| 2008-06-30 | 14.07% |
| 2008-03-31 | 13.65% |
| 2007-12-31 | 14.19% |
| 2007-09-30 | 14.36% |
| 2007-06-30 | 16.90% |
| 2007-03-31 | 16.85% |
| 2006-12-31 | 16.96% |
| 2006-09-30 | 16.43% |
| 2006-06-30 | 15.82% |
| 2006-03-31 | 15.53% |
| 2005-12-31 | 15.64% |
| 2005-09-30 | 16.26% |
| 2005-06-30 | 16.08% |
| 2005-03-31 | 14.87% |
| 2004-12-31 | 13.74% |
| 2004-09-30 | 10.43% |
| 2004-06-30 | 9.63% |
| 2004-03-31 | 9.32% |
| 2003-12-31 | 11.02% |
| 2003-09-30 | 51.20% |
| 2003-06-30 | 55.79% |
